BMC Psychiatry (Mar 2020)

Cross-cultural adaptation and validation of the 3D-CAM Chinese version in surgical ICU patients

  • Dong-Liang Mu,
  • Pan-Pan Ding,
  • Shu-Zhe Zhou,
  • Mei-Jing Liu,
  • Xin-Yu Sun,
  • Xue-Ying Li,
  • Dong-Xin Wang

DOI
https://doi.org/10.1186/s12888-020-02544-w
Journal volume & issue
Vol. 20, no. 1
pp. 1 – 7

Abstract

Read online

Abstract Background Accurate diagnosis of delirium is very important for prevention and treatment. Present study was designed to validate the 3-Minute Diagnostic Interview for CAM-defined Delirium Chinese version (3D-CAM-CN) in surgical ICU patients. Methods In this prospective diagnostic study, the 3D-CAM was translated into Chinese with culture adaption. Two interviewers (Roles A and B) independently administrated 3D-CAM-CN assessment in adult patients from postoperative days 1 to day 3. At the meantime, a panel of psychiatrists diagnosed delirium according to the Diagnostic and Statistical Manual of Mental Disorders-fifth edition as the reference standard. The sensitivity and specificity were calculated to analyze the diagnostic character of the 3D-CAM-CN. Kappa coefficient was used to evaluate interrater reliability. Results Two hundred forty-five adult patients were assessed for at least 2 days, resulting a total of 647 paired-assessments. When compared with the reference standard, the sensitivity and specificity of the 3D-CAM-CN assessment were 87.2 and 96.7%, respectively, by Role A and 84.6 and 97.4%, respectively, by Role B, with good interrater reliability (Kappa coefficient = 0.82, P < 0.001). It also performed well in patients with mild cognitive impairment, with the sensitivity from 85.7 to 100% and the specificity from 95.7 to 96.4%. Conclusion Our results showed that the 3D-CAM-CN can be used as a reliable and accurate instrument for delirium assessment in surgical patients. Trial registration This trail was approved by the Clinical Research Ethic Committee of Peking University First Hospital (No. 2017–1321) and registered on Chinese clinical trial registry on July 6, 2017 ( ChiCTR-OOC-17011887 ).

Keywords